Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–105 of 105 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate to Severe Rheumatoid Arthritis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

NCT03315494
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
SKI-O-703 capsule, Placebo capsule
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 10, 2026, 11:53 PM EDT
Terminated Phase 2 Interventional Results available

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

NCT00083759
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
natalizumab, placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 10, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01885078
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
67
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 10, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 10, 2026, 11:53 PM EDT
Terminated Phase 1 Interventional

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

NCT06087406
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions
Imvotamab, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 10, 2026, 11:53 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

NCT04539964
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Implant Procedure, Conventional Synthetic DMARD, Active stimulation, Non-active stimulation
Procedure · Drug · Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
42
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 10, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

NCT00891020
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 10, 2026, 11:53 PM EDT
Completed Phase 2 Interventional Results available

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

NCT01373151
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab
Drug · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 10, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

NCT02706847
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
103
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 10, 2026, 11:53 PM EDT